|
Establishment of 12 human embryonic stem cell lines, including 2 cell lines on NIH Stem Cell
Registry
Since 1999, CHA BIOTECH has successfully created 12 human embryonic stem (hES) cell lines,
two of which are registered with the National Institutes of Health (NIH) Human Embryonic
Stem
Cell Registry.
Recent stem cell lines have been produced in xenogen-free and
pathogen-
free
conditions
using proprietary methods making them suitable for future human
clinical
application.
Today, the Company is preparing to establish 100 additional clinical-grade hES cell lines having received approval from Korea 's National Embryo Committee (KMHW-2005-13). |
|
 Excellent differentiation technology / genetic manipulation / reprogramming of hES cells
CHA BIOTECH scientists have developed technology to induce differentiation of hES cells into
specific cell types of all three germ layers and to inhibit tumor formation during differentiation.
Our scientific team has also established human embryonic stem cell lines that are not rejected by the immune system.
CHA BIOTECH's researchers are also focused on developing artificial organs using biomaterials, genetically-modified stem cells, large-scale characterization of stem
cells in terms of genomics and proteomics and development of an evaluation system for
preclinical-grade safety and
efficacy tests.
CHA BIOTECH was the nation's first to successfully
restore damaged cranial nerves by
transplanting murine embryonic stem cells into the brains
of living mice.
The Company's future plans are to employ dopaminergic neuronal cells to
develop therapeutic
applications for patients with degenerative brain diseases.
Establishment & clinical applications of adult and fetal-derived stem cell lines
In the field of adult and fetal-derived stem cells, CHA BIOTECH scientists are focused on
research involving the consistent isolation, purification, ex vivo expansion and characterization of cord blood-derived stem cells, germline stem cells, placenta-derived and fetal stem cells.
Our researchers have made extraordinary advancements and witnessed promising results
in the
clinical applications of adult stem cells. In 2005, we initiated Phase I studies of several
IRB-
approved clinical trials using cord blood stem cells to treat patients with stress urinary
incontinence, leukemia and neuronal diseases.
The results and patient outcomes have realized the incredible potential that stem cells offer.
|
